Operational Framework and Feasibility of the GALFLU Study: A Pragmatic Individually Randomized Controlled Trial Evaluating High-Dose Versus Standard-Dose Influenza Vaccination in Older Adults

Narmeen Mallah[1,2,3,4#], PhD, Jacobo Pardo-Seco[1,2,5,6#], PhD, Carmen Rodriguez-Tenreiro-Sánchez[1,2,5,7#], PhD, Iago Giné-Vázquez, PhD[1,2,5], PhD, Susana Mirás-Carballal[8], Marta Piñeiro-Sotelo[8], Martín Cribeiro-González[9], Mónica Conde-Pájaro[10], Juan-Manuel González-Pérez[11], Josefina Lorena Razzini[1,2,5], MD, Irene Rivero-Calle MD, PhD [1,2,5,7], Ana Isabel Dacosta-Urbieta MD[1,2,5,7], Rebecca C Harris, MBioch MSc PhD[12], Matthew M Loiacono, PhD[13], Robertus van Aalst, PhD[13], Joan Manel Farre, PhD[14], Marine Dufournet, PhD[15], Niklas Dyrby Johansen MD, PhD[16,17], Daniel Modin, MD[16,17], Tor Biering-Sørensen, MD, MSc, MPH, PhD [16, 17,18,19], Carmen Duran-Parrondo, Pharm-D[20], Federico Martinón-Torres, MD, PhD (https://orcid.org/0000-0002-9023-581X)[1,2,5,7#], GALFLU trial team[21]

[1] Genetics, Vaccines and Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Galicia, Spain.

[2] WHO Collaborating Centre for Vaccine Safety, Santiago de Compostela, Galicia, Spain.

[3] Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBER-ESP), Madrid, Spain.

[4] Department of Preventive Medicine, University of Santiago de Compostela (USC), Santiago de Compostela, Galicia, Spain.

[5] Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.

[6] GenPoB Research Group, Instituto de Investigación Sanitaria (IDIS), Hospital Clínico Universitario de Santiago (SERGAS), and INCIFOR, Universidade de Santiago de Compostela (USC), 15706 Santiago de Compostela, Galicia, Spain.

[7] Translational Pediatrics and Infectious Diseases, Hospital Clínico Universitario de Santiago (SERGAS) and University of Santiago de Compostela (USC), Santiago de Compostela, Galicia, Spain.

[8] Galician Center for Disease Control and Prevention (CEGACE). Dirección Xeral de Saúde Pública, Consellería de Sanidade, Xunta de Galicia, Galicia, Spain

[9] Department of Communicable Diseases, Dirección Xeral de Saúde Pública, Consellería de Sanidade, Xunta de Galicia, Galicia, Spain.

[10] Dirección Xeral de Recursos Económicos, Servizo Galego de Saúde, Xunta de Galicia, Galicia, Spain.Dirección Xeral de Saúde Pública, Consellería de Sanidade, Xunta de Galicia, Galicia, Spain.

[11] Subdirección de Sistemas y Tecnologías de la Información, Consellería de Sanidade, Xunta de Galicia, Galicia, Spain.

[12] Sanofi Vaccines, Singapore

[13] Sanofi Vaccines, Morristown, NJ, USA

[14] Sanofi Vaccines, Barcelona

[15] Sanofi Vaccines, Lyon, France

[16] Department of Cardiology, Copenhagen University Hospital – Herlev and Gentofte, Copenhagen, Denmark

[17]Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Biomedical

[18] Department of Cardiology, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark

[19] Steno Diabetes Center Copenhagen, Herlev, Denmark

[20] Dirección Xeral de Saúde Pública, Consellería de Sanidade, Xunta de Galicia, Galicia, Spain

21 GALFLU trial team (Annex 1)

Conflicts of interest:

RCH, MML, RvA, MF, and MD are full-time employees of Sanofi and may hold stocks and/or shares in the company. IR-C has received speaking fees from GSK, Moderna, MSD, Pfizer and Sanofi; research grants from AstraZeneca; has acted as subinvestigator in clinical sponsored by Astra-Zeneca, GlaxoSmithKline, Janssen, Medimmune, Moderna, MSD, Novavax, Novartis, Pfizer, Regeneron, Roche, Sanofi Pasteur, and Seqirus with honoraria paid to her institution; and has consulting or advisory relationships with GlaxoSmithKline, MSD, Pfizer and Sanofi. TBS has received research grants from Bayer, Novartis, Pfizer, Sanofi Pasteur, GSK, Novo Nordisk, AstraZeneca, Boston Scientific and GE Healthcare, consulting fees from Novo Nordisk, IQVIA, Parexel, Amgen, CSL Seqirus, GSK and Sanofi Pasteur, and lecture fees from AstraZeneca, Bayer, Novartis, Sanofi Pasteur, GE healthcare and GSK. FM-T has acted as principal investigator for other studies sponsored by Astra-Zeneca, GlaxoSmithKline, Janssen, Medimmune, Moderna, MSD, Novavax, Novartis, Pfizer, Regeneron, Roche, Sanofi Pasteur, and Seqirus, with honoraria paid to his institution; and has consulting or advisory relationships with GlaxoSmithKline, Janssen, Medimmune, Moderna, MSD, Pfizer, Sanofi Pasteur, and Seqirus. Rest of authors have declared no conflict.

Funding statement

The GALFLU study (EU CT number:2023-506977-36-00) is funded by Sanofi through a research grant to the Healthcare Research Institute of Santiago. FM-T research work was also supported by Framework Partnership Agreement between the Consellería de Sanidad de la Xunta de Galicia and GENVIP-IDIS-2021–2024 for the GALFLU study (SERGAS-IDIS 11-october-2023; Spain); ReSVinext: PI16/01569, Enterogen: PI19/01090, OMI-COVI-VAC: PI22/00406 co-funded with FEDER funds; GEN-COVID (IN845D 2020/23), Consorcio Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CB21/06/00103).

Corresponding author:

Prof. Federico Martinón-Torres MD, Ph.D; Hospital Clínico Universitario de Santiago de Compostela; A Choupana s.n.; 15701 Santiago de Compostela, Spain. federico.martinon.torres@sergas.es

Key points:

GALFLU shows the feasibility of large, pragmatic, individually randomized trials and highlights the value of population-based health registries embedded within public health systems, offering randomized real-world evidence to inform vaccine policy, regulatory decisions, and cost-effectiveness analyses for influenza and other vaccines.

Abstract

Background: Optimizing influenza vaccination strategies for older adults remains a public health priority. Whilst the high-dose inactivated influenza vaccine (HD-IIV) has demonstrated superior immunogenicity and efficacy compared to standard-dose inactivated influenza vaccines (SD-IIV), the real-world effectiveness against severe outcomes has mostly relied on observational data and small RCTs, so is yet to be explored within large-scale individually randomised trials, particularly within publicly funded health systems.

Methods: GALFLU is a pragmatic, individually randomized, open-label clinical trial evaluating the effectiveness of HD-IIV versus SD-IIV in adults aged 65–79 years in Galicia, Spain, during the 2023–2024 and 2024-2025 influenza seasons. The study integrated the methodological rigor and efficiency of individual randomization into existing public health infrastructure, and real-time, population-based digital health registries enabled large-scale data capture at low cost and with minimal burden to participants, under real-world conditions.

The main endpoint is relative vaccine effectiveness (rVE) against a composite of influenza- or pneumonia-related hospitalizations. Secondary endpoints involve rVE against hospitalization for any cardio-respiratory disease (composite); hospitalization with laboratory-confirmed influenza; all-cause hospitalization; all-cause mortality; hospitalization for influenza; and hospitalization for pneumonia. Exploratory endpoints include exacerbation of existing conditions and impact on healthcare resource utilisation.

Results: GALFLU demonstrates the feasibility of embedding large-scale, pragmatic randomized controlled trials (RCTs) within routine clinical practice in Galicia, Spain. The design enabled large and efficient recruitment. Total 133,822 participants were randomized, 59,490 in 2023/24 season and 74,986mar in 2024/25 season, all within 4 weeks for 2023/-24 season, and 5 weeks for 2024/-25 season. Follow-up was completed for over 99% of the participants through automated linkage to clinical and laboratory registries.

Conclusions: GALFLU provides a scalable, low-burden model for generating robust real-world evidence from RCTs embedded within public health programs.

This operational framework serves as a blueprint for future comparative vaccine evaluations and supports regulatory and policy decisions with high-quality, population-level data. GALFLU exemplifies how public health systems can evolve into learning health systems by integrating pragmatic trials into routine care.

Trial registration: EU Clinical Trials Register (EU CT number: 2023-506977-36-00); ClinicalTrials.gov Identifier: NCT06141655.

Introduction

Influenza remains a significant global public health concern, with the World Health Organization (WHO) estimating a billion cases and 3–5 million severe cases annually.[1] Vulnerable populations including the elderly, individuals with comorbidities, young children, and the immunocompromised face the greatest risk.[2,3] It is estimated that among individuals aged 75 and older, influenza contributes to between 51.3 and 99.4 annual deaths per 100,000 individuals.[1,4] Vaccine effectiveness (VE) of standard dose influenza vaccines is lower in older than in younger adults (30.6% versus 36.7%),[5] highlighting the need for tailoring vaccination strategies, especially among the elderly.

In older adults, the high-dose inactivated influenza vaccine (HD-IIV) offers deomnstrated superior protection over standard-dose inactivated influneza vaccine (SD-IIV) against laboratory confirmed infection.{DiazGranados, 2014 #13} Data from a meta-analysis of observational and some smaller RCTs also suggest that HD-IIV may reduce influenza-related, pneumonia-related, and all-cause hospitalizations as well as respiratory and cardiovascular outcomes.[6,7] Therefore, vaccines tailored for oldr adult populations, such as HD, are increasingly recommended by health authorities to optimize influenza prevention strategies in aging populations.[8,9] The quadrivalent HD influenza vaccine (QIV-HD; Efluelda®) was approved in Europe in April 2020 for individuals aged 65 and older, and is recommended in Galicia-Spain, the current study region, for individuals aged 80 and older and nursing home citizens aged 60 and older since the 2023/2024 influenza season.[10]

There is a significant public health interest in quantifying the potential impact of HD-IIV versus SD-IIV on clinically relevant outcomes such as influenza- or pneumonia-related hospitalizations in the 65-79 age group. While traditional explanatory trials are valuable for assessing efficacy under ideal conditions, they often involve highly selected participants and strictly controlled environments. As a result, these trials may fail to capture appropriately the heterogeneity of the general population or reflect the administrative and operational realities of routine vaccine delivery within public health programs. Consequently, their findings may have limited applicability to real-world clinical practice and can result in estimates of benefits and harms with a lack of external validity.[11]

In contrast, a pragmatic trial design helps address these limitations by assessing vaccine effectiveness under real-world conditions, thereby enhancing the generalizability of findings to routine clinical practice. By embedding randomization within routine vaccination programs and leveraging population-based healthcare registries for follow-up, pragmatic trials can preserve the rigor of randomized clinical trials while enhancing applicability to everyday clinical practice. Individual randomization is the methodological gold standard for causal inference as it minimizes confounding by evenly distributing known and unknown risk factors between study groups.

Robust evidence about the effectiveness of HD vaccines from individually randomized trials remains scarce. The recent feasibility study in Denmark (DANFLU-1),[12] assessed clinical endpoints in an exploratory fashion but was not powered to detect meaningful differences. DANFLU-2 is an ongoing trial, but alone cannot deliver on globally generalizable results.

To address this evidence gap, the GALFLU trial was initiated—a pragmatic, registry-based, open-label, active-controlled, individually randomized trial designed to evaluate the real-world effectiveness of HD-IIV versus SD-IIV in individuals aged 65 to 79 years in Galicia, Spain.

The availability of population-based health registries in Galicia facilitates the implementation of large-scale pragmatic trials. These registries provide extensive data which are particularly valuable when assessing comparative vaccine effectiveness, where differences in effect size are often modest. Through passive data collection, these registries enable the efficient capture of clinical events without requiring active medical record reviews or direct participant follow-up. This approach also supports the detection of infrequent or hard-to-ascertain endpoints, which may otherwise be impractical to study. Moreover, the large sample sizes of population-based registries increase statistical power, reduce overall development costs for drugs and vaccines, and offer benefits to patients and healthcare systems by delivering the data of importance to these decision makers. . Findings from GALFLU could contribute to cost-effectiveness analyses and inform future influenza vaccination policies for older adults.

Methods

GALFLU is registered in the European Clinical Trial registry under the identification code: 2023-506977-36-00 and in ClinicalTrials.gov: NCT06141655.[13]

Settings and population

GALFLU was conducted in Galicia, an autonomous community in Northwest Spain of nearly 2.7 million inhabitants. The trial was initiated within a collaborative framework involving the Health Research Institute of Santiago de Compostela (IDIS), the Galician Health Service (SERGAS) through the General Directorate of Public Health, and the Galician Regional Vaccination Program.

Healthcare in Galicia is organized in seven sanitary areas and offered through 14 public hospital complexes containing 9,818 beds (latest data for 2022).[14] A unique identification number is attributed to each person upon affiliating with SERGAS, which is then used in all SERGAS registries. 98% of the Galician citizens benefit from SERGAS.[15] Migration is uncommon in the Galician population, decreasing the rate of eventual loss to follow-up of the study participants. The General Public Health Directorate, through the Regional Vaccination Program of Galicia, has a well-established network of vaccination sites where COVID-19 and seasonal flu vaccines are usually administered.

In Galicia, 26.3% of the population is aged 65 years or older, and 5.2% are 85 or older.[16] In the 2022/2023 influenza season, the Galician government vaccination program was expanded to offer HD-IIV vaccine to citizens aged 85 years and above and citizens aged 60 and above who were nursing home residents, while citizens aged 65-84 years were offered SD vaccines.[10]The influenza vaccine acceptance rate among Galicians aged 65 and older was 74.38% in 2023, one of the highest in Europe. Coverage has increased over the past decade, approaching the World Health Organization's target of at least 75%.[8,17] By age group, this target was surpassed in the 80–84 (86.13%) and 85+ (79.80%) age brackets, and nearly reached in the 70–79 group (74.76%).[17] Coverage was lower in the 65–69 (62.48%) and 60–64 (46.29%) age groups.[17]

Study design

GALFLU is a pragmatic, registry-based, open-label, active-controlled, individually randomized trial. This design is particularly well-suited for evaluating vaccines in aging populations, where clinical heterogeneity and comorbidities are common. Definitions of baseline clinical characteristics, medication use, and prior vaccination status are detailed in Supplementary Tables 1–3.

The trial was conducted over two influenza seasons (2023/24 and 2024/25), with participants randomized 1:1 each season to receive either the quadrivalent HD-IIV (Efluelda®) or the routine quadrivalent SD. Randomization was centralized using a computer-generated block scheme. Participants from the first season could re-enroll and were re-randomized. Enrollment occurred from 26th October to 26th November in 2023/-24 season, and from 30th October to 2nd December in 2024/-25 season, with follow-up for primary and secondary endpoints beginning 14 days post-vaccination and continuing through May 31.

Recruitment strategy

Galician administrative registries and electronic health records are used for eligibility identification, streamlined recruitment processes, and data collection. Participants were contacted via personalized SMS messages containing QR codes, enabling flexible vaccination appointments and participant identification. A dedicated application facilitated participant randomization. Each season, 450,000 Galicians within the target age range (65-79 years) were initially invited to participate by text message. To promote awareness and participation, the study was supported by tailored outreach efforts, including informative posters and leaflets, a web portal (www.galfu.gal), media releases, and a dedicated call center (Supplementary Material File 1).

Conducted in collaboration with the General Directorate of Public Health, all study procedures, including recruitment, inclusion, and vaccination, were embedded within the existing Galician healthcare infrastructure. Participants were enrolled

at 14 vaccination sites by 190 sub-investigators coordinated by three central leads, optimizing both efficiency and regional coverage.

Potential participants had the chance of receiving all relevant information about the trial before their vaccination appointment through telephone text mesage, via web, in person or through a 24/7 call-centre. Comprehensive details were made available on the official webpage of the Galician Influenza Regional Vaccination Program, which included a downloadable informed consent form. Additionally, a dedicated website (www.galfu.gal) provided information about the trial along with a section for frequently asked questions.[18] A free contact phone number was also provided for further inquiries and to support potential participants.

At the vaccination visit, individuals expressing interest in the study were provided with a patient information sheet and an informed consent form. A trained medical professional from the research team provided verbal explanations, ensured sufficient time for participants to read the information, and answered all inquiries. Enrollment proceeded only after participants had received complete information and voluntarily agreed to participate by signing the informed consent form. Eligible individuals who chose not to participate or withdrew before vaccination, were able to access the usual routine vaccinations from the regional programme at the same site and visit.

Ethics and regulatory

GALFLU clinical trial was ethically approved by the Comité de ética de la investigación con medicamentos de Galicia (CEIm-G), Ethics Committee of Galicia (Spain), under the registration code 2023/374, before its implementation. Fully approval was obtained under Clinical Trials Regulation (EU) No 536/2014 (CTR), being the involved national competent authority the Spanish Agency of Medicines and Medical Devices (AEMPS).

GALFLU complies with the principles of the Declaration of Helsinki and undergoes monitoring according to the International Conference on Harmonization guidelines for Good Clinical Practice. Informed consent was obtained before vaccination. Participation in the study was voluntary, and only

individuals who accepted signing the informed consent were recruited. Participants could withdraw their consent to participate in the study at any time.

The confidentiality of the data of the subjects participating in the trial is guaranteed, ensuring compliance with Organic Law 3/2018, of December 5, Protection of personal data and guarantee of digital rights as well as the General Data Protection Regulation (GDPR). Any patient data transferred from the site was fully pseudonymized and handled according to current regulations.

Inclusion criteria

Given the pragmatic nature of GALFLU, no specific exclusion criteria were defined for this trial. However, participants are required to meet the following conditions: (i) be between 65 and 79 years of age, (ii) reside in Galicia, (iii) be ineligible to receive the QIV-HD as part of standard care, and (iv) provide signed informed consent. Potentially eligible participants were assessed by a trained medical professional, who also evaluated any potential contraindications to influenza vaccination by routine clinical practice.

HD and SD vaccine administration

For pragmatic reasons, the vaccines evaluated in this study were administered within routine clinical practice as part of the Galician Regional Vaccination Program. Vaccination followed the indications outlined in the respective marketing authorizations, which could include co-administration with COVID-19 vaccines or boosters, as per local guidance and recommendations

The investigational vaccine was the quadrivalent HD-IIV (Efluelda®, Sanofi , Paris). For both the 2023/24 and 2024/25 seasons, Influvac tetra® (Abbot Biologicals, The Netherlands) was the influenza vaccine used in subjects 65-79 years old in Galicia, and it was therefore the vaccine used as the comparator in the quadrivalent SD-IIV arm.

As GALFLU is an open-label trial, neither investigators, healthcare professionals, nor trial participants were blinded to vaccine allocation. Given that hospitalization

endpoints are severe outcomes objectively measured using routinely collected registry data, the risk of bias is considered negligible despite the open-label design.

Primary objective

GALFLU was designed and powered to evaluate the rVE of HD-IIV versus SD-IIV against influenza- or pneumonia-related hospitalizations as a composite endpoint in adults aged 65 to 79 years.

Secondary objectives

GALFLU's secondary objectives are to evaluate the rVE of HD-IIV versus SD-IIV in reducing the risk of the following endpoints in adults aged 65 to 79: i) hospitalization for any cardio-respiratory disease as a composite endpoint; ii) hospitalization with a laboratory confirmed influenza; iii) all-cause hospitalization; iv) all-cause mortality; v) hospitalization for influenza; and vi) hospitalization for pneumonia.

Exploratory objectives

GALFLU's exploratory objectives encompass evaluating the rVE of HD-IIV versus SD-IIV against the risk of the following endpoints: (1) hospitalization for influenza or pneumonia as a composite endpoint (alternate definition); (2) hospitalization for pneumonia (alternate definition); (3) hospitalization for influenza (alternate definition); (4) hospitalization for any respiratory disease; (5) hospitalization for any cardiovascular disease; (6) hospitalization for myocardial infarction; (7) hospitalization for heart failure; (8) hospitalization for atrial fibrillation; (9) hospitalization for stroke; (10) major adverse cardiovascular events (MACE) defined as a composite of hospitalization for acute myocardial infarction, hospitalization for stroke, and cardiovascular death; (11) MACE defined as a composite of hospitalization for acute myocardial infarction, hospitalization for stroke, hospitalization for heart failure, and cardiovascular death (alternate MACE

definition #1); (12) MACE defined as a composite of hospitalization for acute myocardial infarction, hospitalization for stroke, and all-cause death (alternate MACE definition #2); (13) hospitalization requiring mechanical ventilation; (14) laboratory-confirmed influenza; (15) laboratory-confirmed pneumococcal pneumonia; (16) laboratory-confirmed COVID-19; (17) cardio-respiratory mortality; (18) respiratory mortality; (19) cardiovascular mortality; and (20) in-hospital mortality for any cause.

Healthcare resource consumption objective

GALFLU aimed to assess healthcare resource use and related costs between HD-IIV and SD-IIV arms. Outcomes include: (1) any hospitalization; (2) hospitalizations requiring mechanical ventilation; (3) duration of hospitalization stays for: i) Influenza or pneumonia; ii) any cardio-respiratory disease; iii) Influenza and iv) pneumonia; (4) primary care visits; (5) nursing home admission following any all-cause hospitalization; and (6) anti-infective use.

Endpoints

All endpoints corresponding to the primary, secondary, and exploratory objectives are summarized in **Table 1**. Any hospitalization-based events with an associated COVID-19 ICD-10 discharge diagnosis code (B342, B972 – any position) were not considered an eligible endpoint for assessment.

Sample size calculation

The study aimed to randomize at least 114,011 participants across two influenza seasons (~57,000 per season). This sample size was to provide ≥80% statistical power to assess the primary objective, based on: i) an rVE of HD-IIV vs SD-IIV of 18%,; ii) 18% rVE as the threshold for cost-effectiveness per Galician health authorities; iii) a one-sided Type I error of 0.025; iv) superior protection defined by the lower bound of the rVE confidence interval >0%; v) a 1:1 allocation ratio; and vi) an estimated 0.8% attack rate for the primary endpoint in the SD-IIV group

based on 2022-2023 flu season Galician registry among vaccinated 65-79 years old participant.

Data sources and linkage

Data were obtained from SERGAS registries (see Supplementary Text 1). Each participant received a unique subject code upon enrollment and was randomized via electronic lists. The personal data linkage was securely stored in a restricted-access identification code list managed by the research team.

Safety assessment

Both the HD-IIV and SD-IIV used in the GALFLU trial were approved for use in Galicia. Accordingly, safety was monitored using a pragmatic, registry-based approach. Each participant was assessed by an independent expert committee that evaluated occurrenceof serious adverse events (SAEs) and serious adverse reactions (SARs) up to three months after vaccination (+/- 15 days) using data extracted from SERGAS registries. Details in supplementary Text 2.

Statistical analysis

Continuous baseline variables were summarized using means and standard deviations or medians and interquartile ranges. Binary or categorical variables will be compared using frequencies and proportions. Unless otherwise specified, p-values <0.05 (including alpha-adjustment if required) will be considered statistically significant.

For rVE calculations, only the participants' first events in each endpoint category will be considered. rVE will be calculated as: rVE = (1-(CHD /NHD)/(CSD/NSD)) x 100%. CHD and CSD describe the numbers of endpoints registered in the HD-IIV and SD-IIV arm, respectively. NHD and NSD describe the numbers of participants in the HD-IIV and SD-IIV arms, respectively. For all endpoints, an rVE point estimate and a 95% alpha-adjusted confidence interval (CI) will be reported. P-values will only be reported for endpoints tested in the hierarchical

testing procedure. The CI will be calculated using the Clopper-Pearson method.[20] Inference will be based on the lower limit of the alpha-adjusted CIs. HD-IIV will be considered superior to SD-IIV if the lower bound of the estimated rVE alpha-adjusted CI is >0%.

Several sensitivity analyses will be conducted to test the robustness of rVE estimates. These include i) extending the end of the follow-up period from May 31 to August 31 to capture late-season events, and ii) restricting it to peak influenza activity using surveillance data (based on test positivity thresholds) or hospitalization data (centered around the peak week of influenza or pneumonia admissions in adults aged 65–79). Additional analyses include applying survival analysis methods using Cox regression and log-rank tests, including endpoints with associated COVID-19 discharge diagnoses (for primary and secondary endpoints only), accounting for within-participant correlation across multiple seasons, redefining the follow-up period to start from randomization, including the 14 days post-vaccination usually excluded, and assessing endpoints accounting for all events in a given season as opposed to only the first event. Details in supplementary text 3.

Results

During the first season of the GALFLU trial 181 research nurses were trained in study procedures during a general site initiation visit and 14 trainings on site were performed before the start of the recruitment. This training covered all the procedures of the trial. In addition, GCP training was requested for all the members of the study team. Recruitment started the 26th of October of 2023 and the recruitment goal (57,326 participants) was achieved in 24 days. Recruitment continued for a further 6 additional days, reaching final recruitment of 59,490 subjects. Recruitment rates were different among the 14 vaccination sites. Individual recruitment goals were defined before the start of recruitment for each recruitment site taking into account the influenza vaccination rate of each region and assuming a participation rate to the trial of a 17.5%. 12 of 14 vaccination sites reached the target recruitment goal during the recruitment period. 16 days were

needed to achieve the recruitment goal in the fastest of the participating sites. Recruitment was not stopped upon reaching site-level recruitment targets, i sites continued recruitment until the end of the recruitment period. Different recruitment rates were observed during the recruitment period, with a maximum of 4,136 participants/day. This achievement was only possible thanks to the development of an application able to randomize several subjects at the same time by different users in all the vaccination sites. No major issues were found during the randomization period. Research nurses in the vaccination sites were supported by a research nurse coordinator in each vaccination site and with the support of the GALFLU coordination team available 24/7 during the recruitment period.

The same schedule was replicated during the second season, with even greater recruitment success. Some logistical improvements and human resource allocation changes were implemented based on first season learnt lessons. During this last season all the vaccination sites achieved the site-level recruitment goal during the recruitment period. This was possible thanks to theexpertise of the research nurses that joined to the trial during the 1st season and the training of new nurses that were interested in taking part in the trial. 187 research nurses were recruited and trained to take part in the 2nd season of GALFLU trial. The recruitment objective (57,036 subjects) was achieved 19 days after the start of recruitment (day 20), but recruitment continued until the end of routine vaccination appointments encompassing an additional 8 days, and achieving 131.5% of the target recruitment objective (74,986 subjects). Higher recruitments rates were observed during all the days of the recruitment period compared to the daily recruitment rates observed during the 1st season, with a peak recruitment of 3863 participants/da . During this season 12 days were needed to achieve the recruitment goal in the 1st recruitment site which achieved the purposed goal.

Discussion

GALFLU, to the best of our knowledge, is the first statistically powered pragmatic trial assessing the rVE of HD influenza vaccines against a range of clinically relevant endpoints, including influenza- and pneumonia-related hospitalizations specifically addressing the 65-79 years old general population.

Influenza poses a significant public health burden, particularly among older adults. Vaccination remains the most effective strategy for controlling infectious diseases; however, this population often exhibits a reduced immune response, diminishing VE (30.6% in older adults versus 36.7% in younger adults),[5] highlighting the need for tailoring vaccination strategies.

To meet this need, HD-IIV has been developed to improve immune response and clinical outcomes. Nevertheless, evidence from real-world settings and in the most severe clinical outcomes is crucial to support health authorities in adopting the most suitable vaccination strategies.

A pragmatic trial design such as that employed in GALFLU addresses these limitations by evaluating interventions in more diverse and representative populations under real, routine clinical settings. Findings from pragmatic trials support decisions that reflect the complexities and variability of actual patient populations and care settings. In addition, pragmatic trials allow for the identification of specific patient subgroups who can benefit the most from the intervention, enhancing the precision and impact of public health recommendations.

The GALFLU trial exemplifies a pragmatic approach, aligning with the nine domains of the Pragmatic–Explanatory Continuum Indicator Summary 2 Tool- a widely used framework designed to help researchers design clinical trials that fit their purpose.[21] In GALFLU, the eligibility criteria V were intentionally broad to mirror real-world clinical practice. The trial included participants aged 65 years and older who would typically be considered for influenza vaccination in routine primary care. This inclusive approach reflects actual clinical practice and enhances generalizability.

GALFLU was implemented within the existing Galician healthcare infrastructure, including 14 regional vaccination sites. This setting is representative of usual care environments. To ensure adequate recruitment and timely vaccine delivery, additional healthcare personnel were hired. While this may represent a departure from standard healthcare resource levels, no additional screening visits or research-specific outreach were required in this trial, thereby preserving the study's pragmatic nature.

Participants were identified through administrative registries and electronic health records- a real-world approach consistent with routine clinical workflows. GALFLU employed recruitment methods such as personalized SMS invitations with QR codes and a dedicated call center, mirroring strategies commonly used in public health communication during routine vaccination campaigns. To further enhance vaccine uptake, GALFLU also utilized leaflets, media campaigns, recruitment supporting personnel in the vaccination sites and other promotional materials. These additional efforts might reflect real-world efforts to boost vaccination rates during seasonal campaigns.

The delivery of both the HD-IIV and SD-IIV vaccines was flexible and aligned with routine practice. Trained healthcare personnel from the Galician Health Service were responsible for obtaining informed consent, randomizing, administering either vaccine and registering the vaccination. This approach was designed to resemble real-world conditions and clinical performance. To retrieve data on study outcomes, electronic health records were utilized, and no additional contact with the participants was made for this purpose. This ensures that the GALFLU trial maintains a highly pragmatic design by limiting follow-up to what would normally occur in usual care.

Given the significant burden of influenza, particularly among the elderly, the primary outcome of the GALFLU trial, hospitalization due to influenza or pneumonia, is highly relevant both to participants and to broader public health objectives. The selection of the primary outcome is a critical aspect of trial design, and a pragmatic approach emphasizes choosing an outcome that holds clear and direct importance from the patient's perspective.[21] The endpoint hospitalization with laboratory confirmed influenza was initially included as an exploratory endpoint but in the revised version of the statistical analysis plan it was included as secondary endpoint as an alternative approach to the influenza hospitalization definition. Finally, the use of all available data from all participants included in the study in the analysis is a characteristic of highly pragmatic studies.

All the milestones achieved during the GALFLU trial demonstrate that routine practice and research activities can work together in pragmatic clinical trials. It is also important to highlight the commitment with the vaccination and with the

research of the regional health authorities, healthcare providers and potential population of the trial in Galicia, essential for the success of the trial.

GALFLU aligns with the broader shift toward learning health systems, where routine practice and research coexist and inform each other dynamically. Furthermore, GALFLU's reliance on routinely collected electronic health records, with no additional patient contact, establishes a precedent for sustainable, low-disruption data collection aligned with modern data governance standards. The trial's digital recruitment strategy, which integrated SMS invitations and QR-code linked appointments, represents a model of scalable, tech-enabled public health research, potentially applicable to other vaccination campaigns or health interventions. One of GALFLU's most innovative contributions is its demonstration that real-world clinical trials can maintain strong internal validity when built upon robust digital health infrastructure and well-established public health systems. This approach is particularly relevant in the current global context where healthcare systems are under pressure to balance cost-effectiveness, population health, and operational feasibility.

Conclusions

Successful delivery of the GALFLU operational framework demonstrates high feasibility for large-scale individually randomized influenza vaccine trials in older adult populations in Galicia, reinforcing the potential for large, pragmatic, individually randomized, database-linked trials to inform evidence-based vaccine policy decision-making. This operational framework serves as a blueprint for future comparative vaccine evaluations and supports regulatory and policy decisions with high-quality, population-level data. GALFLU exemplifies how public health systems can evolve into learning health systems by integrating pragmatic trials into routine care.

References

1. World Health Organization. Influenza (Seasonal). 03 October 2023 2023. https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal) (accessed 19 December 2024).
2. European Centre for Disease Prevention and Control. Risk groups for severe influenza. 2023. https://www.ecdc.europa.eu/en/seasonal-influenza/prevention-and-control/vaccines/risk-groups (accessed 23 December 2024).
3. U.S. Centers for Disease Control and Prevention (CDC). People at Increased Risk for Flu Complications. 2024. https://www.cdc.gov/flu/highrisk/index.htm (accessed 23 December 2024).
4. Iuliano AD, Roguski KM, Chang HH, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet 2018; 391(10127): 1285-300.
5. Guo J, Chen X, Guo Y, et al. Real-world effectiveness of seasonal influenza vaccination and age as effect modifier: A systematic review, meta-analysis and meta-regression of test-negative design studies. Vaccine 2024; 42(8): 1883-91.
6. Skaarup KG, Lassen MCH, Modin D, et al. The relative vaccine effectiveness of high-dose vs standard-dose influenza vaccines in preventing hospitalization and mortality: A meta-analysis of evidence from randomized trials. J Infect 2024; 89(1): 106187.
7. Lee JKH, Lam GKL, Yin JK, Loiacono MM, Samson SI. High-dose influenza vaccine in older adults by age and seasonal characteristics: Systematic review and meta-analysis update. Vaccine X 2023; 14: 100327.
8. European Centre for Disease Prevention and Control. Seasonal influenza vaccination recommendations and coverage rates in EU/EEA Member States. 2023. https://www.ecdc.europa.eu/en/publications-data/seasonal-influenza-vaccination-recommendations-and-coverage-rates-eueea-member (accessed 30 December 2024).
9. U.S. Centers for Disease Control and Prevention. Flu and People 65 Years and Older. 2024. https://www.cdc.gov/flu/highrisk/65over.htm (accessed 27 December 2024).

10. Servizo Galego de Saúde . Gripe. Información Basica de Campaña [Flu. Basic information of the camapign]. 2024. https://gripe.sergas.es/Contidos/Informacion-basica-da-campana (accessed 24 July 2025).
11. Ford I, Norrie J. Pragmatic Trials. N Engl J Med 2016; 375(5): 454-63.
12. Johansen ND, Modin D, Nealon J, et al. Feasibility of randomizing Danish citizens aged 65-79 years to high-dose quadrivalent influenza vaccine vs. standard-dose quadrivalent influenza vaccine in a pragmatic registry-based setting: rationale and design of the DANFLU-1 Trial. Pilot Feasibility Stud 2022; 8(1): 87.
13. European Clinical Trials Registry. 2023-506977-36-00 - GALFLU - Pragmatic Randomized Trial to Evaluate the Effectiveness of High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in adults aged 65 to 79 years in Galicia, Spain - Ongoing, recruiting. 2023. https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en (accessed 02 January 2024).
14. Instituto Gallego de Estadistica [Galician Health Institute]. Hospitais [Hospitals]. 2022. https://www.ige.gal/web/mostrar_actividade_estatistica.jsp?idioma=gl&codigo=0202001 (accessed 18 June 2025).
15. Galician Health Service (SERGAS). Activities report SERGAS 2018 [Memoria actividades SERGAS 2018]. 2018. https://www.sergas.es/A-nosa-organizacion/Documents/832/MemoriaActividade2018.pdf (accessed 18 June 2025).
16. Instituto Gallego de Estadistica [Galician Health Institute]. Población [Population]. 2023. https://www.ige.gal/igebdt/esq.jsp?c=0201001001&ruta=verTabla.jsp?COD=142&R=0[2023];2[all];9915[n0]&C=1[0]&F=&OP=1&B=1# (accessed 30 December 2024).
17. Xunta de Galicia. Consellería de Sanidad [Galician Health Ministry]. CAMPAÑA DE VACINACIÓN FRONTE Á GRIPE 2023. Informe final, abril 2024. [Influenza vaccine campagin 2023. Final report, April 2024]. 2024. https://www.sergas.es/Saude-publica/Informes-coberturas-antigripais (accessed 30 December 2024).

18. Xunta de Galicia. Consellería de Sanidad [Galician Health Ministry]. GALFLU. 2023. https://galflu.gal/ (accessed 02 January 2024).
19. DiazGranados CA, Robertson CA, Talbot HK, Landolfi V, Dunning AJ, Greenberg DP. Prevention of serious events in adults 65 years of age or older: A comparison between high-dose and standard-dose inactivated influenza vaccines. Vaccine 2015; 33(38): 4988-93.
20. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998; 17(8): 857-72.
21. Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M. The PRECIS-2 tool: designing trials that are fit for purpose. BMJ 2015; 350: h2147.

Table 1. Endpoints under primary, secondary, and exploratory objectives of the GALFLU study.

Endpoint	ICD-10 codes	Diagnosis type	Inpatient, outpatient, or minimum required length of hospitalization and other criteria	Timeframe
Primary objective endpoint				
Influenza or pneumonia hospitalization [composite endpoint]	J09-J18	Primary discharge diagnosis	Inpatient, at least 1 night	≥14 days after vaccination and up to May 31 the following year
Secondary objective endpoint				
Cardio-respiratory disease hospitalization* [composite endpoint]	I11, I13, I20-I25, I30-I31, I33, I38-I42, I46-I50, I60-I69, I74, J00-J06, J09-J18, J20-J22, J40-J47, J80-J81, J85-J86, J96	Primary discharge diagnosis	Inpatient, at least 1 night	≥14 days after vaccination and up to May 31 the following year
All-cause hospitalization	Any	Any	Inpatient, at least 1 night	≥14 days after vaccination and up to May 31 the following year
All-cause mortality	-	-	-	≥14 days after vaccination and up to May 31 the following year
Influenza hospitalization	J09-J11	Primary discharge diagnosis	Inpatient, at least 1 night	≥14 days after vaccination and up to May 31 the following year
Pneumonia hospitalization	J12-J18	Primary discharge diagnosis	Inpatient, at least 1 night	≥14 days after vaccination and up to May 31 the following year
Laboratory-confirmed influenza hospitalization#	-	Positive influenza microbiology test	Inpatient, at least 1 night	≥14 days after vaccination and up to May 31 the following year
Exploratory objectives endpoints				
Influenza or pneumonia hospitalization [composite endpoint] (alternate definition)	J09-J18	Primary or secondary discharge diagnosis	Inpatient, at least 1 night	≥14 days after vaccination and up to May 31 the following year
Influenza hospitalization (alternate definition)	J09-J11	Primary or secondary discharge diagnosis	Inpatient, at least 1 night	≥14 days after vaccination and up to May 31 the following year

Table 1. Endpoints under primary, secondary, and exploratory objectives of the GALFLU study.

Endpoint	ICD-10 codes	Diagnosis type	Inpatient, outpatient, or minimum required length of hospitalization and other criteria	Timeframe
Pneumonia hospitalization (alternate definition)	J12-J18	Primary or secondary discharge diagnosis	Inpatient, at least 1 night	≥14 days after vaccination and up to May 31 the following year
Respiratory disease hospitalization	J00-J06, J09-J18, J20-J22, J40-J47, J80-J81, J85-J86, J96	Primary discharge diagnosis	Inpatient, at least 1 night	≥14 days after vaccination and up to May 31 the following year
Cardiovascular disease hospitalization	I11, I13, I20-I25, I30-I31, I33, I38-I42, I46-I50, I60-I69, I74	Primary discharge diagnosis	Inpatient, at least 1 night	≥14 days after vaccination and up to May 31 the following year
Myocardial infarction hospitalization	I21	Primary discharge diagnosis	Inpatient, at least 1 night	≥14 days after vaccination and up to May 31 the following year
Heart failure hospitalization	I50	Primary discharge diagnosis	Inpatient, at least 1 night	≥14 days after vaccination and up to May 31 the following year
Atrial fibrillation hospitalization	I48	Primary discharge diagnosis	Inpatient, at least 1 night	≥14 days after vaccination and up to May 31 the following year
Stroke hospitalization	I63-I64	Primary discharge diagnosis	Inpatient, at least 1 night	≥14 days after vaccination and up to May 31 the following year
Major adverse cardiovascular events (MACE)	Hospitalizations: I21, I63-I64 Deaths: Any I-diagnosis as cause of death	For hospitalizations: Primary discharge diagnosis	For hospitalizations: Inpatient, at least 1 night	≥14 days after vaccination and up to May 31 the following year
MACE (alternate definition #1)	Hospitalizations: I21, I50, I63-I64 Deaths: Any I-diagnosis as cause of death	For hospitalizations: Primary discharge diagnosis	For hospitalizations: Inpatient, at least 1 night	≥14 days after vaccination and up to May 31 the following year
MACE (alternate definition #2)	Hospitalizations: I21, I63-I64 Deaths: All-cause	For hospitalizations: Primary discharge diagnosis	For hospitalizations: Inpatient, at least 1 night	≥14 days after vaccination and up to May 31 the following year

Table 1. Endpoints under primary, secondary, and exploratory objectives of the GALFLU study.

Endpoint	ICD-10 codes	Diagnosis type	Inpatient, outpatient, or minimum required length of hospitalization and other criteria	Timeframe
Hospitalization requiring mechanical ventilation	-	-	Any duration, procedural code "BGDA" registered at any point during hospitalization	≥14 days after vaccination and up to May 31 the following year
Laboratory-confirmed pneumococcal pneumonia	-	-	Positive test for streptococcus pneumonia	≥14 days after vaccination and up to May 31 the following year
Laboratory-confirmed COVID-19	-	-	Positive COVID-19 test	≥14 days after vaccination and up to May 31 the following year
In-hospital mortality	-	-	Death (all-cause) while being hospitalized for at least 1 night	≥14 days after vaccination and up to May 31 the following year
Cardio-respiratory mortality	Any I- or J-diagnosis as a cause of death	-	-	≥14 days after vaccination and up to May 31 the following year
Respiratory mortality	Any J-diagnosis as a cause of death	-	-	≥14 days after vaccination and up to May 31 the following year
Cardiovascular mortality	Any I-diagnosis as cause of death	-	-	≥14 days after vaccination and up to May 31 the following year

*: *For cardio-respiratory hospitalizations, a broad list of ICD-10 codes is currently specified. ICD: International Classification of Diseases.*

#: *This endpoint was initially included as an exploratory endpoint but in the revised version of the statistical analysis plan it was included as secondary endpoint as an alternative approach to the influenza hospitalization definition.*